Cortexyme, Inc(NASDAQ:CRTX) 
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase I...
Website: http://www.cortexyme.com
Founded: 2012
Full Time Employees: 37 (May 2021)
CEO: Casey Crawford Lynch
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.27
H 1.36
L 1.20
C 1.24
V 137,410
10EMA 1.24
20EMA 1.24
60EMA 1.24
120EMA 1.24
250EMA 1.24